摘要:
In an effort to prepare effective nonsteroidal antiestrogens without intrinsic estrogenicity and with greater antagonism than the triarylethylenes (tamoxifen), four (E)- and (Z)-1,1-dichloro-2-phenyl-2-[4-(2-diethylaminoethoxy) phenyl]-3-(4-methoxyphenyl)cyclopropane analogs of the antiestrogen MER 25, of which two of the compounds had a 4-heptafluorotolyl group in the ct-ring, were prepared. The (E)- and (Z)-gem-dichlorotriarylcyclopropanes were tested for their ability to inhibit the growth of estrogen receptor (ER)-positive MCF-7E3 and ER-negative MDA-MB-231 human breast cancer cells in culture. All compounds, except 18E, exhibited a statistically significant (P < 0.01) reduction in estradiol-stimulated growth (antiestrogenic activity) at 1.0 mu M concentration in the MCF-7E3 cells: 11Z (88%), 11E (106%), 18Z (65%), and the test compounds 7A(Z) (85%), 7A(E) (53%), MRL 37 (91%), MER 25 (71%), and ICI 182,780 (102%). Inhibition of estradiol-stimulated growth at concentrations lower than 1.0 mu M was demonstrated by 11E, MER 25, and ICI 182,780. Compound 11E produced weak inhibition at 0.1 nM (19%) and nearly complete inhibition (79-112%) over a concentration range of 1.0 to 100 nM. MER 25 produced inhibition of estradiol-stimulated growth at 1.0 (39%), 10 (102%), and 100 nM (100%) concentrations. ICI 182,780 completely inhibited estrogen-stimulated growth from 0.1 nM to 1.0 mu M concentrations. Two compounds exhibited estrogenic activity: 18E (from 1.0 nM to 1.0 mu M concentrations) and MER 25, which had antiestrogenic action at the lower concentration ranges, but exhibited estrogenic properties at 100 nM to 1.0 mu M concentrations. None of the test compounds or standards were active in the MDA-MB-231 cell line at the concentrations studied (0.01 nM to 1.0 mu M). In addition, none of the compounds inhibited cell growth below control in the MCF-7E3 cell line. The results from both cell lines suggest that the test compounds are devoid of any antitumor properties, which is thought to be mediated through a nonreceptor mechanism. Analog 11E has the potential to be useful in the treatment of hormone-responsive breast cancer. (C) 1998 Academic Press.